Personalis, Inc. (PSNL) Guidance & Earnings Results
On 2026-05-07 Personalis, Inc. reaffirmed guidance: "FY2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45K, clinical revenue…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
PSNLPersonalis, Inc.Follow PSNL — free
—
Price chart with a free account
- Market cap
- 1.7B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 7 May 26 | Reaffirmed | FY2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45K, clinical revenue $10-11M · full year |
| 26 Feb 26 | Raised | FY2026 revenue $78-80M; clinical revenue $10-11M; clinical volume 43-45K tests · full year |
| 4 Nov 25 | Lowered | FY2025 revenue guidance reduced to $68-73M from $70-80M; clinical tests reimbursed cut to $1.5-2M from $3-6M · full year |
| 5 Aug 25 | Lowered | FY25 revenue $70-80M from $80-90M; pharma revenue $52-58M from $62-64M; clinical tests $3-6M from $3-10M; gross margin 22-24% (vs 32% FY24); net loss ~$85M from $83M; cash usage ~$75M (vs $47M FY24); Q3 revenue $12-14M; Q3 pharma $11-13M; Q3 population sequencing ~$1M · full year |
Personalis, Inc. — questions
- What guidance did Personalis, Inc. give?
- On 2026-05-07: "FY2026 guidance reaffirmed: total revenue $78-80M, clinical tests 43-45K, clinical revenue $10-11M"
- When does Personalis, Inc. report earnings?
- Personalis, Inc.'s next earnings report is expected on 2026-11-10.
Every figure on this page comes from Personalis, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.